01 / Research notes
What the policy says about blends
BPC-157 acetate and TB-500 acetate are separately discussed under specific conditions. The interim policy's single-ingredient requirement is a condition on each compounded product, so a vial containing both does not qualify under that provision.
Two separate products would still need independent clinical, pharmacy, and regulatory assessment. The policy does not recommend a combination or guarantee access to either substance.
02 / Research notes
What the evidence says
The direct human musculoskeletal evidence for each peptide is limited. Published studies do not establish a combined treatment benefit or a validated blend protocol. Mechanistic theories and animal data cannot fill that gap.
A product advertised as a stack may also raise identity, concentration, sterility, and impurity questions. FDA has raised possible immunogenicity and impurity concerns for these substances.
03 / Research notes
The better question for an injury
A slow-healing injury can have a cause that changes the care plan. A clinician can assess the diagnosis, prior treatment, rehabilitation needs, infection or circulation concerns, and evidence-based options.
If you have already used a peptide product, tell the clinician its exact label, source, timing, and any new symptoms. This helps evaluate possible adverse events and avoids overlooking other care.
Common questions
Does the HHS update allow a BPC-157/TB-500 blend?
No. The interim policy's single-listed-ingredient condition does not cover a combined product.
Is the combination proven to heal faster?
No controlled human evidence establishes that outcome for a compounded combination.
Can two separate products be prescribed?
That requires an individualized clinical and regulatory assessment; the interim policy itself does not recommend or guarantee it.
Sources and important information
Compounded drugs are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. HHS's interim policy is conditional and may change. Treatment through Jonathan Larson MDPC requires clinical evaluation; a licensed provider decides whether any prescription is medically necessary and appropriate. This guide is informational, not medical advice.